Is it time now to use a risk adjusted strategy in CLL?

Is immediate treatment indicated for patients who present with “high risk” disease?

What biomarkers determine who requires immediate therapy?

Do prognostic markers also predict for response to therapy?

Is the same treatment indicated for all CLL patients irrespective of molecular profile?

Are the assays for the molecular prognostic factors ready to be used outside clinical trials?